Furthermore, we analyzed data on the treatment of patients with MPN + CML or CML + MPN following a diagnosis of secondary CML or BCR::ABL1-negative MPN (Supplemental Fig. 3). This evidence concerns the gene ABL1 and myeloproliferative disorder.